Anzeige
Mehr »
Mittwoch, 25.06.2025 - Börsentäglich über 12.000 News
TAO +1.800?%, SBAR +85?%, CYK +280?% - jetzt startet KORA auf Unternehmensebene durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 881535 | ISIN: US75886F1075 | Ticker-Symbol: RGO
Tradegate
25.06.25 | 13:29
449,10 Euro
-0,07 % -0,30
1-Jahres-Chart
REGENERON PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
REGENERON PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
447,50451,9013:32
447,50451,9013:32

Aktuelle News zur REGENERON PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
10:46FDA approves Sanofi and Regeneron's Dupixent for bullous pemphigoid6
DiRegeneron Pharmaceuticals, Inc.: Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization3
MoSanofi/Regeneron's Dupixent granted FDA approval for bullous pemphigoid7
Fr$100 Invested In Regeneron Pharmaceuticals 20 Years Ago Would Be Worth This Much Today6
FrFDA Approves Regeneron Sanofi Treatment For Rare Autoimmune Skin Disorder8
FrSanofi & Regeneron's Dupixent Gets FDA Nod for Bullous Pemphigoid6
REGENERON PHARMACEUTICALS Aktie jetzt für 0€ handeln
FrRegeneron, Sanofi win FDA label expansion for Dupixent against rare skin disorder2
FrSanofi and Regeneron's Dupixent gets FDA approval for rare skin disease4
FrSanofi und Regeneron erhalten weitere US-Zulassung für Dupixent363DJ Sanofi und Regeneron erhalten weitere US-Zulassung für Dupixent Von Adria Calatayud DOW JONES--Sanofi und ihr Partner Regeneron Pharmaceuticals können ihren Entzündungshemmer Dupixent in...
► Artikel lesen
FrRegeneron, Sanofi: FDA Approves Dupixent To Treat Adult Patients With Bullous Pemphigoid246PARIS (dpa-AFX) - Regeneron Pharmaceuticals Inc. (REGN) and French drug major Sanofi S.A. (SNYNF,SNY) announced Friday that the U.S. Food and Drug Administration has approved Dupixent (dupilumab)...
► Artikel lesen
FrRegeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)138Approval based on pivotal results showing improvements in sustained disease remission and reductions in itch and oral corticosteroid use compared to placebo in adults with BP BP is a chronic, debilitating...
► Artikel lesen
18.06.REGENERON PHARMACEUTICALS, INC. - 8-K, Current Report4
17.06.FDA clears CSL's swelling disease drug; Regeneron loses 23andMe auction6
17.06.Regeneron is said to have declined a higher bid for 23andMe after Wojcicki's offer13
16.06.Regeneron declines to make higher bid for 23andMe after Wojcicki's $305 million offer3
16.06.Silver Scott Mines Inc: Silver Scott Health, Inc. Unveils Health Trust NFT to Empower Patient Data Control in Response to Regeneron's $600 Million 23andMe Bid309FRANKLIN, NJ / ACCESS Newswire / June 16, 2025 / Silver Scott Mines, Inc. (OTC PINK:SILS), a diversified digital technology company focused on healthcare, blockchain, and real-world asset tokenization...
► Artikel lesen
16.06.Former CEO wins bidding war for 23andMe, beating Regeneron6
16.06.EHA 2025: Regeneron's Lynozyfic with Amgen's Kyprolis combo emerges for R/R MM16
15.06.Regeneron Pharmaceuticals, Inc.: Dupixent (dupilumab) Demonstrated Superiority Over Xolair (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase ...161New late-breaking data at EAACI showed Dupixent outperformed Xolair across all primary and secondary efficacy endpoints of CRSwNP and in all asthma-related endpoints Dupixent also outperformed Xolair...
► Artikel lesen
12.06.Thermo Fisher: Regeneron Genetics Center Selects Olink Explore HT for Landmark Proteomics Study of 200,000 Patient Samples333Large-scale study aims to create comprehensive map of the human proteome to monitor changes reflecting human health and disease Thermo Fisher Scientific, the world leader in serving science, today...
► Artikel lesen
Weiter >>
394 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,5